Skip to main content

Cookies on the NHS England and NHS Improvement website

We’ve put some small files called cookies on your device to make our site work.

We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.

Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose.

 

  • Home
  • News
  • Publications
  • Statistics
  • Blogs
  • Events
  • Contact us
NHS England
  • About us
  • Our work
  • Commissioning
  • Get involved
  • Insights Platform

Our advice for clinicians on the coronavirus is here.
If you are a member of the public looking for information and advice about coronavirus (COVID-19), including information about the COVID-19 vaccine, go to the NHS website. You can also find guidance and support on the GOV.UK website.

Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Document first published:
9 July 2020
Page updated:
22 July 2020
Topic:
Commissioning, Medicine, Specialised commissioning
Publication type:
Policy or strategy, Report

Document

Clinical commissioning policy: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Clinical commissioning policy: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 105 KB
  • 9 pages

Document

Clinical panel report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Clinical panel report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 23 KB
  • 2 pages

Document

CPAG summary report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

CPAG summary report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 124 KB
  • 8 pages

Document

Evidence report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Evidence report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 21 KB
  • 2 pages

Document

Evidence review: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Evidence review: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 547 KB
  • 35 pages

Document

Public consultation report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Public consultation report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 32 KB
  • 2 pages

Document

Engagement report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

Engagement report: Ustekinumab for refractory Crohn’s disease in pre-pubescent children

  • PDF
  • 37 KB
  • 3 pages
  • Terms and conditions
  • Privacy and cookies
  • Social media and comment moderation
  • How could this website work better for you?
  • Accessibility statement
  • Open Government Licence v3.0
  • Follow us on Twitter
  • Visit us on LinkedIn
  • Watch videos on YouTube
  • View photos on Flickr
  • All RSS
NHS website